Keros Therapeutics Announces Pricing of Public Offering of Common Stock
November 12, 2020 22:11 ET
|
Keros Therapeutics, Inc.
LEXINGTON, Mass., Nov. 12, 2020 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on the discovery, development and...
Keros Therapeutics Announces Proposed Public Offering of Common Stock
November 10, 2020 17:12 ET
|
Keros Therapeutics, Inc.
LEXINGTON, Mass., Nov. 10, 2020 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on the discovery, development and...
Keros Therapeutics Reports Recent Business Highlights and Third Quarter 2020 Financial Results
November 10, 2020 16:17 ET
|
Keros Therapeutics, Inc.
LEXINGTON, Mass., Nov. 10, 2020 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros” or the “Company”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on the discovery,...
Keros Therapeutics to Present at the Virtual 62nd American Society of Hematology Annual Meeting and Exposition
November 04, 2020 16:01 ET
|
Keros Therapeutics, Inc.
LEXINGTON, Mass., Nov. 04, 2020 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on the discovery, development and...
Keros Therapeutics, Inc. Announces Dosing of First Participants in Phase 2 Clinical Trial of KER-050 in Myelodysplastic Syndromes (MDS)
October 20, 2020 08:00 ET
|
Keros Therapeutics, Inc.
First two participants dosed in a Phase 2 clinical trial of KER-050 in MDSInitial data expected by mid-2021 LEXINGTON, Mass., Oct. 20, 2020 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros”...
Keros Therapeutics to Present at the H.C. Wainwright 22nd Annual Global Investment Conference
September 14, 2020 07:01 ET
|
Keros Therapeutics, Inc.
LEXINGTON, Mass., Sept. 14, 2020 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on the discovery, development and...
Keros Therapeutics Presents Results from Preclinical Studies Investigating KER-012 at the American Society for Bone and Mineral Research 2020 Annual Meeting
September 11, 2020 16:01 ET
|
Keros Therapeutics, Inc.
LEXINGTON, Mass., Sept. 11, 2020 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros” or the “Company”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on the discovery,...
Keros Therapeutics Reports Recent Business Highlights and Second Quarter 2020 Financial Results
August 13, 2020 07:00 ET
|
Keros Therapeutics, Inc.
LEXINGTON, Mass., Aug. 13, 2020 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on the discovery, development and...
Keros Therapeutics to be Featured on The Balancing Act's "Behind the Mystery" Rare Disease Series
August 10, 2020 08:00 ET
|
Keros Therapeutics, Inc.
LEXINGTON, Mass., Aug. 10, 2020 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros” or the “Company”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on the discovery,...
Keros Therapeutics, Inc. Announces Completion of Dosing of Planned Cohorts in KER-047 Phase 1 Trial and Provides Program Update
August 04, 2020 08:00 ET
|
Keros Therapeutics, Inc.
LEXINGTON, Mass., Aug. 04, 2020 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros” or the “Company”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on the discovery,...